Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases (Q42716993)

5 November 2017

title

Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases (English)

1 reference

5 November 2017

Lars Bärfacker

1

1 reference

5 November 2017

Alexander Kuhl

2

1 reference

5 November 2017

Alexander Hillisch

3

1 reference

5 November 2017

Rolf Grosser

4

1 reference

5 November 2017

Santiago Figueroa-Pérez

5

1 reference

5 November 2017

Heike Heckroth

6

1 reference

5 November 2017

Adam Nitsche

7

1 reference

5 November 2017

Jens-Kerim Ergüden

8

1 reference

5 November 2017

Heike Gielen-Haertwig

9

1 reference

5 November 2017

Karl-Heinz Schlemmer

10

1 reference

5 November 2017

Joachim Mittendorf

11

1 reference

5 November 2017

Holger Paulsen

12

1 reference

5 November 2017

Johannes Platzek

13

1 reference

5 November 2017

Peter Kolkhof

14

1 reference

5 November 2017

publication date

12 July 2012

1 reference

5 November 2017

1 reference

5 November 2017

volume

7

1 reference

5 November 2017

issue

8

1 reference

5 November 2017

page(s)

1385-1403

1 reference

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

5 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Eplerenone in patients with systolic heart failure and mild symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

The evolution of aldosterone antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

1,4-Dihydropyridines: Effects of Chirality and Conformation on the Calcium Antagonist and Calcium Agonist Activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Discovery of Novel Cyanodihydropyridines as Potent Mineralocorticoid Receptor Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

The binding of [3H]nitrendipine to receptors for calcium channel antagonists in the heart, cerebral cortex, and ileum of rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Pharmacologic profile of amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

The preclinical development of bicalutamide: pharmacodynamics and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Mechanisms of ligand specificity of the mineralocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Ueber die Synthese pyridinartiger Verbindungen aus Acetessigäther und Aldehydammoniak

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Photosensitized oxidations of substituted pyrroles: unanticipated radical-derived oxygenated products

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Ruthenium porphyrin catalyzed intramolecular carbenoid C[bond]H insertion. Stereoselective synthesis of cis-disubstituted oxygen and nitrogen heterocycles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Design and synthesis of novel alpha1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Potential therapeutic antioxidants that combine the radical scavenging ability of myricetin and the lipophilic chain of vitamin E to effectively inhibit microsomal lipid peroxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Synthesis and quantitative structure-activity relationships of antiallergic 2-hydroxy-N-1H-tetrazol-5-ylbenzamides and N-(2-hydroxyphenyl)-1H-tetrazole-5-carboxamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Structural basis of spirolactone recognition by the mineralocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

7 January 2021

Antialdosterones: incidence and prevention of sexual side effects

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

7 January 2021

On the methylation of 3-cyano-6-hydroxypyridine-2(1H)-ones

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

7 January 2021

1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

7 January 2021

Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200081

7 January 2021

Enantioselective Total Synthesis of (-)-Finerenone using Asymmetric Transfer Hydrogenation

0 references

Identifiers

DOI

10.1002/CMDC.201200081

1 reference

5 November 2017

1 reference